Your browser doesn't support javascript.
loading
Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures.
Georgeson, Peter; Harrison, Tabitha A; Pope, Bernard J; Zaidi, Syed H; Qu, Conghui; Steinfelder, Robert S; Lin, Yi; Joo, Jihoon E; Mahmood, Khalid; Clendenning, Mark; Walker, Romy; Amitay, Efrat L; Berndt, Sonja I; Brenner, Hermann; Campbell, Peter T; Cao, Yin; Chan, Andrew T; Chang-Claude, Jenny; Doheny, Kimberly F; Drew, David A; Figueiredo, Jane C; French, Amy J; Gallinger, Steven; Giannakis, Marios; Giles, Graham G; Gsur, Andrea; Gunter, Marc J; Hoffmeister, Michael; Hsu, Li; Huang, Wen-Yi; Limburg, Paul; Manson, JoAnn E; Moreno, Victor; Nassir, Rami; Nowak, Jonathan A; Obón-Santacana, Mireia; Ogino, Shuji; Phipps, Amanda I; Potter, John D; Schoen, Robert E; Sun, Wei; Toland, Amanda E; Trinh, Quang M; Ugai, Tomotaka; Macrae, Finlay A; Rosty, Christophe; Hudson, Thomas J; Jenkins, Mark A; Thibodeau, Stephen N; Winship, Ingrid M.
Afiliação
  • Georgeson P; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Harrison TA; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Pope BJ; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Zaidi SH; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Qu C; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Steinfelder RS; Melbourne Bioinformatics, The University of Melbourne, Carlton, VIC, Australia.
  • Lin Y; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Joo JE; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Mahmood K; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Clendenning M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Walker R; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Amitay EL; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Berndt SI; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Brenner H; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Campbell PT; Melbourne Bioinformatics, The University of Melbourne, Carlton, VIC, Australia.
  • Cao Y; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Chan AT; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Chang-Claude J; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
  • Doheny KF; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
  • Drew DA; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Figueiredo JC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • French AJ; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Gallinger S; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Giannakis M; German Cancer Consortium (DKTK), German Cancer Research Center(DKFZ), Heidelberg, Germany.
  • Giles GG; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Gsur A; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
  • Gunter MJ; Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
  • Hoffmeister M; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Hsu L; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Huang WY; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Limburg P; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Manson JE; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Moreno V; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Nassir R; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Nowak JA; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Obón-Santacana M; University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany.
  • Ogino S; Center for Inherited Disease Research (CIDR), Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Phipps AI; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Potter JD; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Schoen RE; Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Sun W; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Toland AE; Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Trinh QM; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Ugai T; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • Macrae FA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Rosty C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hudson TJ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Jenkins MA; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Thibodeau SN; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Winship IM; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Nat Commun ; 13(1): 3254, 2022 06 06.
Article em En | MEDLINE | ID: mdl-35668106
ABSTRACT
Carriers of germline biallelic pathogenic variants in the MUTYH gene have a high risk of colorectal cancer. We test 5649 colorectal cancers to evaluate the discriminatory potential of a tumor mutational signature specific to MUTYH for identifying biallelic carriers and classifying variants of uncertain clinical significance (VUS). Using a tumor and matched germline targeted multi-gene panel approach, our classifier identifies all biallelic MUTYH carriers and all known non-carriers in an independent test set of 3019 colorectal cancers (accuracy = 100% (95% confidence interval 99.87-100%)). All monoallelic MUTYH carriers are classified with the non-MUTYH carriers. The classifier provides evidence for a pathogenic classification for two VUS and a benign classification for five VUS. Somatic hotspot mutations KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic MUTYH carriers compared with non-carriers (p = 2 × 10-23 and p = 6 × 10-11, respectively). Here, we demonstrate the potential application of mutational signatures to tumor sequencing workflows to improve the identification of biallelic MUTYH carriers.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / DNA Glicosilases Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / DNA Glicosilases Idioma: En Ano de publicação: 2022 Tipo de documento: Article